TABLE 2

Effect of CNTFAx15 administration for 3 days (0.1 and 1.0 μg · g−1 · day−1) or 7 days (0.1 and 0.3 μg · g−1 · day−1) on circulating insulin and blood glucose concentrations in diet-induced obese C57BL/6J and UCP1-DTA mice

GroupsInsulin (ng/ml)Glucose (mg/dl)
3-day studies
    DIO-C57 24 h after last treatment
        PBS2.14 ± 0.39117.2 ± 5.2
        C-0.11.21 ± 0.29*121.6 ± 3.3
        C-1.01.02 ± 0.0691.3 ± 2.3§
        PF to C-1.00.82 ± 0.0398.3 ± 3.6
    DIO-C57 4 days after last treatment
        PBS2.52 ± 0.31#NSA
        C-0.12.16 ± 0.36#NSA
        C-1.02.61 ± 0.41#NSA
        PF to C-1.05.26 ± 1.17NSA
7-day studies
    DIO-C57 24 h after last treatment (cohort 1)
        PBS5.99 ± 1.09123.6 ± 5.7
        C-0.10.91 ± 0.23§125.6 ± 10.4**
        C-0.30.42 ± 0.07§92.8 ± 5.4††
        PF to C-0.30.72 ± 0.16§81.6 ± 3.7
    DIO-C57 4 days after last treatment (cohort 2)
        PBS4.61 ± 0.51141.2 ± 4.8
        C-0.11.80 ± 0.49130.2 ± 5.4
        C-0.32.81 ± 0.79*113.4 ± 5.7‡‡§§
        PF to C-0.32.08 ± 0.4396.2 ± 2.1§
    UCP1-DTA 24 h after last treatment (cohort 1)
        PBS1.95 ± 0.58111.6 ± 6.6
        C-0.10.84 ± 0.33116.0 ± 8.4
        C-0.31.09 ± 0.3096.0 ± 0.7*§§#
        PF to C-0.30.49 ± 0.0963.7 ± 5.6***
  • Data are means ± SE, analyzed by ANOVA. Data were obtained 24 h after the last treatment (cohort 1) or in the posttreatment period (4 days after the last treatment, cohort 2).

  • *

    * P < 0.05 vs. the PBS-treated group;

  • P < 0.0001 vs. the pair-fed group;

  • P < 0.01 and

  • §

    § P < 0.0001 vs. the PBS-treated group;

  • P < 0.0001 vs. the 0.1-μg·g−1·day−1 CNTFAx15–treated group;

  • P < 0.001 vs. the PBS-treated group;

  • #

    # P < 0.01 vs. the pair-fed group;

  • **

    ** P < 0.001 vs. the pair-fed group;

  • ††

    †† P < 0.01; vs. the 0.1-μg·g−1·day−1 CNTFAx15–treated group;

  • ‡‡

    ‡‡ P < 0.05 vs. the pair-fed group;

  • §§

    §§ P < 0.05 vs. the 0.1-μg·g−1·day−1 CNTFAx15–treated group. C-0.1, 0.1-μg·g−1·day−1 CNTFAx15–treated group; C-1.0, 1.0-μg·g−1·day−1 CNTFAx15–treated group; C-0.3, 0.3- μg·g−1·day−1 CNTFAx15–treated group; NSA, no sample available; PF, pair-fed.